Genzyme Files Suit Against TKT for Glucocerebrosidase Patent Infringement

27-Jan-2005

Genzyme Corp. announced that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certain cell culture processes involved in the manufacture of glucocerebrosidase. TKT is conducting a clinical trial in Israel of its investigational gene-activated glucocerebrosidase (GA-GCB) for the treatment of Gaucher disease. Genzyme believes that TKT infringes Genzyme's patent by importing into Israel and using in Israel the GA-GCB product manufactured by the processes protected by Genzyme's patent.

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances